Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Buildings (2016)

Lisata Therapeutics filings provide 4 years of Buildings readings, the most recent being $13.0 million for Q4 2016.

  • For the quarter ending Q4 2016, Buildings rose 12.98% year-over-year to $13.0 million, compared with a TTM value of $13.0 million through Dec 2016, up 12.98%, and an annual FY2016 reading of $13.0 million, up 12.98% over the prior year.
  • Buildings hit $13.0 million in Q4 2016 for Lisata Therapeutics, up from $11.5 million in the prior quarter.
  • The five-year high for Buildings was $13.0 million in Q4 2016, with the low at $9.9 million in Q4 2012.
  • Median Buildings over the past 3 years was $11.5 million (2015), compared with a mean of $11.4 million.
  • The sharpest move saw Buildings rose 0.24% in 2012, then rose 12.98% in 2016.
  • Year by year, Buildings stood at $9.9 million in 2012, then increased by 15.97% to $11.5 million in 2015, then increased by 12.98% to $13.0 million in 2016.
  • According to Business Quant data, Buildings over the past three periods came in at $13.0 million, $11.5 million, and $9.9 million for Q4 2016, Q4 2015, and Q4 2012 respectively.